Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.055 -0.095 (-4.42%) Market Cap: 413.83 Mil Enterprise Value: 370.70 Mil PE Ratio: 0 PB Ratio: 7.09 GF Score: 31/100

Taysha Gene Therapies Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 11, 2022 / 03:45PM GMT
Release Date Price: $5.79 (-2.03%)
Gil Blum
Needham & Company, LLC - Analyst

Good morning, everybody. My name is Gil Blum, and I'm a senior biotech analyst here at Needham & Company covering the immuno-oncology and gene therapy sectors. It is my pleasure to have with me today Taysha's management team, including CEO, RA Session; Suyash Prasad, Chief Medical Officer; and Kamran Alam, Chief Financial Officer. (Conference Instructions)

Questions & Answers

Gil Blum
Needham & Company, LLC - Analyst

So with that, RA, could you please provide an introduction for Taysha, the company's origin and kind of the primary focus?

RA Session II
Taysha Gene Therapies, Inc. - CEO

Sure, sure. No, absolutely. And Gil, thank you, and thanks to Needham for having us today. So I'm RA Session, I'm Founder/CEO of Taysha Gene Therapies. Taysha Gene Therapies is a spinout of UT Southwestern based here in Dallas, Texas, particularly, the gene therapy group there, which is led by Dr. Steven Gray and Berge Minassian. Steve has a long story and history of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot